問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間：2023-09-19

葉裕民Yeh, Yu-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • i5485111@gmail.com

Recruiting Trial

185Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉裕民

List

332Cases

2015-02-19 - 2019-06-25

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

Suspended1Sites

2020-09-22 - 2024-03-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-10-01 - 2027-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
針對錯配修復功能(pMMR)/非微衛星高度不穩定(non-MSI-H)之局部晚期或轉移性大腸直腸癌(mCRC)患者,評估ABT301併用Tislelizumab與Bevacizumab的安全性與療效之開放性.多中心.第一/二期臨床試驗

  • Condition/Disease

    第 1 部分：*評估在 pMMR/non-MSI-H 大腸直腸癌患者中，遞增劑量的 ABT-301 與固定劑量的 Tislelizumab（200 mg，靜脈輸注）和 Bevacizumab（7.5 mg/kg，靜脈輸注，每 3 週一次）合併使用時的安全性及耐受性。*確定 ABT-301 的最大耐受劑量 (MTD) 並選擇其建議的第二期劑量 (RP2D)。第 2 部分：*評估兩種劑量/方案的 ABT-301 與 Tislelizumab 和 Bevacizumab 合併使用的療效。

  • Test Drug

    膠囊劑 靜脈輸注液 靜脈輸注液

Participate Sites
7Sites

Recruiting7Sites

2022-11-30 - 2027-03-31

Phase I/II

Completed
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    注射劑 注射液

Participate Sites
4Sites

Recruiting4Sites

2022-02-01 - 2025-01-27

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2023-04-01 - 2026-03-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-03-31 - 2026-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-01-06 - 2026-09-05

Phase III

Active
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Selpercatinib (LY3527723)

Participate Sites
14Sites

Recruiting14Sites

2016-12-23 - 2022-07-31

Phase I

Completed
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    LY3300054

Participate Sites
2Sites

Terminated2Sites

1 12 13 14 15 16 34
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB